TABLE 3.
Seroconversion sensitivity of the HIV rapid assay
| Seroconversion panel (no. of bleeds) | No. of positive samples/total no. of samples
|
|
|---|---|---|
| Rapid assay | HIV-1 and HIV-2 EIAa | |
| Boston Biomedica | ||
| PRB908 (6) | 1/6 | 1/6 |
| PRB916 (6) | 2/6 | 2/6 |
| PBR917 (5) | 2/5 | 2/5 |
| PBR923 (13) | 4/13 | 5/13b |
| PRB924 (8) | 3/8 | 3/8 |
| PRB926 (6) | 2/6 | 2/6 |
| PBR929 (7) | 1/7 | 2/7c |
| PRB932 (9) | 5/9 | 5/9 |
| NABI | ||
| SVO-241 (7) | 4/7 | 4/7 |
| SVO-331 (6) | 0/6 | 1/6d |
| 4888 (7) | 6/7 | 6/7 |
| 37748 (6) | 5/6 | 5/6 |
| Total | 35/86 | 38/86 |
a
Abbott Laboratories recombinant HIV-1/2 EIA (3A77).
b
The rapid assay was positive one bleed (37 days) later than the bleed with which the EIA was positive.
c
The rapid assay was positive one bleed (3 days) later than the bleed with which the EIA was positive.
d
The last bleed (20 days past the first bleed) of the seroconversion panel was detected by EIA but not by the rapid assay.